[{"id":"7b687780-b61c-439e-9b4e-196b803f25c3","acronym":"PAveMenT","url":"https://clinicaltrials.gov/study/NCT04360941","created_at":"2023-12-22T20:17:07.096Z","updated_at":"2024-07-02T16:35:25.341Z","phase":"Phase 1","brief_title":"PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer","source_id_and_acronym":"NCT04360941 - PAveMenT","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" PD-L1 • PIK3CA • TMB • PTEN • RB1","pipe":" | ","alterations":" PD-L1 expression • PIK3CA mutation • PD-L1 negative • RB1 mutation • PTEN expression • PIK3CA expression • PIK3CA mutation + PTEN mutation","tags":["PD-L1 • PIK3CA • TMB • PTEN • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PIK3CA mutation • PD-L1 negative • RB1 mutation • PTEN expression • PIK3CA expression • PIK3CA mutation + PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Bavencio (avelumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 08/11/2020","start_date":" 08/11/2020","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-12-22"},{"id":"55442488-1d80-4dbc-ae5e-2273f0f75787","acronym":"","url":"https://clinicaltrials.gov/study/NCT01802320","created_at":"2021-01-18T07:58:45.783Z","updated_at":"2024-07-02T16:36:55.387Z","phase":"Phase 2","brief_title":"Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery","source_id_and_acronym":"NCT01802320","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • PIK3CA • PTEN","pipe":" | ","alterations":" BRAF mutation • PIK3CA mutation • PTEN mutation • PTEN expression • PIK3CA expression","tags":["KRAS • BRAF • PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • PIK3CA mutation • PTEN mutation • PTEN expression • PIK3CA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MK-2206"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 06/01/2015","primary_completion_date":" 06/01/2015","study_txt":" Completion: 08/05/2015","study_completion_date":" 08/05/2015","last_update_posted":"2019-09-20"},{"id":"b6dfc4a4-9444-4afb-ba81-847d531a5a05","acronym":"PIKHER2","url":"https://clinicaltrials.gov/study/NCT01589861","created_at":"2021-01-18T06:47:09.000Z","updated_at":"2024-07-02T16:37:24.069Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer","source_id_and_acronym":"NCT01589861 - PIKHER2","lead_sponsor":"Institut Paoli-Calmettes","biomarkers":" HER-2 • PIK3CA • PTEN","pipe":" | ","alterations":" HER-2 positive • PIK3CA mutation • PTEN mutation • AKT1 overexpression • PIK3CA expression • PIK3CA overexpression • PTEN negative","tags":["HER-2 • PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • PIK3CA mutation • PTEN mutation • AKT1 overexpression • PIK3CA expression • PIK3CA overexpression • PTEN negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • lapatinib • buparlisib (AN2025)"],"overall_status":"Suspended","enrollment":" Enrollment 106","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 01/01/2018","primary_completion_date":" 01/01/2018","study_txt":" Completion: 01/01/2018","study_completion_date":" 01/01/2018","last_update_posted":"2017-03-28"},{"id":"106fafe4-38a9-4b51-8e9c-d218fa4c01da","acronym":"","url":"https://clinicaltrials.gov/study/NCT00897988","created_at":"2021-01-18T03:26:47.322Z","updated_at":"2024-07-02T16:37:24.433Z","phase":"","brief_title":"DNA Analysis of Tumor Tissue Samples From Patients With Human Papilloma Virus-Associated Cancer of the Oropharynx","source_id_and_acronym":"NCT00897988","lead_sponsor":"Vanderbilt University Medical Center","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation • PIK3CA expression","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PIK3CA expression"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 04/01/2006","start_date":" 04/01/2006","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2017-03-14"}]